PMC:7105881 / 23392-23779 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"736","span":{"begin":119,"end":127},"obj":"Species"},{"id":"737","span":{"begin":268,"end":276},"obj":"Species"},{"id":"738","span":{"begin":281,"end":289},"obj":"Species"},{"id":"743","span":{"begin":75,"end":90},"obj":"Disease"}],"attributes":[{"id":"A736","pred":"tao:has_database_id","subj":"736","obj":"Tax:694009"},{"id":"A737","pred":"tao:has_database_id","subj":"737","obj":"Tax:694009"},{"id":"A738","pred":"tao:has_database_id","subj":"738","obj":"Tax:1335626"},{"id":"A743","pred":"tao:has_database_id","subj":"743","obj":"MESH:D001102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"d that antibodies induced by some of these vaccines mediate enhancement of viral infection in vitro, as in the case of SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising safety concerns for the development of full-length S protein-based subunit vaccines against SARS-CoV and MERS-CoV. In contrast, RBD-based subunit vaccines comprise the major critical neutralizing domain (Du and "}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T96","span":{"begin":229,"end":236},"obj":"Body_part"}],"attributes":[{"id":"A96","pred":"fma_id","subj":"T96","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"d that antibodies induced by some of these vaccines mediate enhancement of viral infection in vitro, as in the case of SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising safety concerns for the development of full-length S protein-based subunit vaccines against SARS-CoV and MERS-CoV. In contrast, RBD-based subunit vaccines comprise the major critical neutralizing domain (Du and "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T94","span":{"begin":75,"end":90},"obj":"Disease"},{"id":"T95","span":{"begin":81,"end":90},"obj":"Disease"},{"id":"T96","span":{"begin":119,"end":127},"obj":"Disease"},{"id":"T97","span":{"begin":268,"end":276},"obj":"Disease"}],"attributes":[{"id":"A94","pred":"mondo_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A95","pred":"mondo_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A96","pred":"mondo_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A97","pred":"mondo_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"d that antibodies induced by some of these vaccines mediate enhancement of viral infection in vitro, as in the case of SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising safety concerns for the development of full-length S protein-based subunit vaccines against SARS-CoV and MERS-CoV. In contrast, RBD-based subunit vaccines comprise the major critical neutralizing domain (Du and "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T100","span":{"begin":229,"end":236},"obj":"Chemical"}],"attributes":[{"id":"A100","pred":"chebi_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"d that antibodies induced by some of these vaccines mediate enhancement of viral infection in vitro, as in the case of SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising safety concerns for the development of full-length S protein-based subunit vaccines against SARS-CoV and MERS-CoV. In contrast, RBD-based subunit vaccines comprise the major critical neutralizing domain (Du and "}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T34","span":{"begin":75,"end":90},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"d that antibodies induced by some of these vaccines mediate enhancement of viral infection in vitro, as in the case of SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising safety concerns for the development of full-length S protein-based subunit vaccines against SARS-CoV and MERS-CoV. In contrast, RBD-based subunit vaccines comprise the major critical neutralizing domain (Du and "}

{"project":"2_test","denotations":[{"id":"32265848-17049691-36511098","span":{"begin":141,"end":145},"obj":"17049691"},{"id":"32265848-22311359-36511099","span":{"begin":161,"end":165},"obj":"22311359"}],"text":"d that antibodies induced by some of these vaccines mediate enhancement of viral infection in vitro, as in the case of SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising safety concerns for the development of full-length S protein-based subunit vaccines against SARS-CoV and MERS-CoV. In contrast, RBD-based subunit vaccines comprise the major critical neutralizing domain (Du and "}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T446","span":{"begin":7,"end":17},"obj":"GO:0042571"},{"id":"T447","span":{"begin":75,"end":80},"obj":"NCBITaxon:10239"},{"id":"T448","span":{"begin":119,"end":127},"obj":"SP_10"},{"id":"T449","span":{"begin":227,"end":236},"obj":"PG_1"},{"id":"T450","span":{"begin":268,"end":276},"obj":"SP_10"},{"id":"T451","span":{"begin":281,"end":289},"obj":"SP_9"},{"id":"T452","span":{"begin":372,"end":378},"obj":"SO:0000417"},{"id":"T15997","span":{"begin":7,"end":17},"obj":"GO:0042571"},{"id":"T12282","span":{"begin":75,"end":80},"obj":"NCBITaxon:10239"},{"id":"T70149","span":{"begin":119,"end":127},"obj":"SP_10"},{"id":"T81971","span":{"begin":227,"end":236},"obj":"PG_1"},{"id":"T97763","span":{"begin":268,"end":276},"obj":"SP_10"},{"id":"T46109","span":{"begin":281,"end":289},"obj":"SP_9"},{"id":"T75353","span":{"begin":372,"end":378},"obj":"SO:0000417"}],"text":"d that antibodies induced by some of these vaccines mediate enhancement of viral infection in vitro, as in the case of SARS-CoV (Kam et al., 2007; Jaume et al., 2012), raising safety concerns for the development of full-length S protein-based subunit vaccines against SARS-CoV and MERS-CoV. In contrast, RBD-based subunit vaccines comprise the major critical neutralizing domain (Du and "}